Testing the Addition of Anti-Cancer Drug, ZEN003694 (ZEN-3694) and PD-1 Inhibitor (Pembrolizumab), to Standard Chemotherapy (Nab-Paclitaxel) Treatment in Patients With Advanced Triple-Negative Breast Cancer
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)
City of Hope Medical Center
Astellas Pharma Inc
Pfizer
Amgen
University of Rochester
University of Utah
Shanghai Zhongshan Hospital
Xijing Hospital
TCRCure Biopharma Ltd.
Jiangsu Hansoh Pharmaceutical Co., Ltd.
NYU Langone Health
University of California, San Diego
Sun Yat-sen University
Taiho Pharmaceutical Co., Ltd.
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Affiliated Cancer Hospital of Shantou University Medical College